Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31664571 | 0.78 | TNKS2 (0.61) | ABCG2KMT2AMEN1ATMNQO2 | |
| SCHEMBL2799080 | 0.78 | TNKS2 (0.61) | ABCG2KMT2AMEN1ATMNQO2 | |
| SCHEMBL3777652 | 0.77 | KDM4E (0.46) | ABCG2PDE3BPDE3ACA1CA4 | |
| SCHEMBL13429106 | 0.75 | KMT2A (0.53) | ABCG2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL9213988 | 0.75 | GPR84 (0.41) | ATMPDE3BPDE3ACA1CA4 | |
| SCHEMBL433885 | 0.75 | TNKS2 (0.62) | TNKS2CYP2A6PDE3BPDE3ACYP1A2 | |
| SCHEMBL16108649 | 0.74 | ABCG2 (0.50) | ABCG2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL12969925 | 0.74 | ATM (0.64) | ABCG2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL27030100 | 0.74 | KDM4E (0.45) | NQO2TNKS2ARPDE3BPDE3A | |
| SCHEMBL30945579 | 0.74 | KDM4E (0.45) | NQO2TNKS2ARPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110467569-B | Preparation method and application of substituted quinoline-2 (1H) -ketone compound | 上海特化医药科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| CN-106588765-A | Method for hydroxylation of nitrogen oxide C2-position | 天津科技大学 | 2017-04-26 | — | — | CN | disclosed |
| WO-2016034512-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2016-03-10 | — | — | WO | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | CHIRON CORPORATION | 2005-03-10 | — | — | US | disclosed |
| US-6800760-B2 | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | CHIRON CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6774237-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES INHIBITORS; ANGIOGENESIS INHIBITORS, ANTICARCINOGENIC AGENTS | CHIRON CORPORATION | 2004-08-10 | — | — | US | disclosed |
| US-6762194-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | CHIRON CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
| EP-1317442-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002022598-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-0125052-B1 | DOPAMINERGIC CARBOSTYRILS AND A PROCESS FOR PREPARING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1988-01-27 | — | — | EP | disclosed |
| EP-0125052-A2 | Dopaminergic carbostyrils and a process for preparing them | SMITHKLINE BECKMAN CORPORATION (US) | 1984-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | VEGFA, FLT1, KDR | ABCG2 106/4885KMT2A 3981/4885MEN1 2515/4885 |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | KDR, FLT4, FLT1 | ABCG2 2165/4885KMT2A 741/4885MEN1 2988/4885 |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | BRD4, BRPF3, BRD3 | ABCG2 572/4885KMT2A 404/4885MEN1 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.